Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 4
1988 2
1989 12
1990 10
1991 11
1992 23
1993 21
1994 24
1995 17
1996 27
1997 32
1998 48
1999 59
2000 67
2001 52
2002 55
2003 55
2004 73
2005 68
2006 105
2007 98
2008 124
2009 193
2010 241
2011 243
2012 231
2013 201
2014 166
2015 169
2016 175
2017 167
2018 148
2019 73
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

2,713 results
Results by year
Filters applied: . Clear all
Page 1
Hematologic adverse effects of clopidogrel.
Balamuthusamy S and Arora R. Am J Ther 2007 - Review. PMID 17303978
Among the thienopyridines, clopidogrel is considered to be a safer alternative to ticlopidine due to its decreased incidence of hematologic adverse effects. ...Early recognition and prompt initiation of treatment can be life saving in patients who have hematologic adverse effects to clopidogrel. ...
Among the thienopyridines, clopidogrel is considered to be a safer alternative to ticlopidine due to its decreased incidence of hemat …
Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel.
Batchelor R, et al. Aliment Pharmacol Ther 2018. PMID 30178881
BACKGROUND: Clopidogrel's anti-platelet effects may be attenuated by a pharmacokinetic interaction with co-prescribed proton pump inhibitors, which inhibit oxidative pathways that convert clopidogrel into its active metabolites. ...The primary outcome was association between PPI monotherapy and any adverse cardiovascular event. The secondary outcome was association between proton pump inhibitor monotherapy and acute myocardial infarction. ...
BACKGROUND: Clopidogrel's anti-platelet effects may be attenuated by a pharmacokinetic interaction with co-prescribed proton pump inh …
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis
Ding L and Peng B. Eur J Neurol 2018. PMID 29855121
Risk ratios (RRs) for the outcomes of stroke recurrence, major bleeding and intracranial bleeding were calculated based on the DerSimonian and Laird random effects model. ...
Risk ratios (RRs) for the outcomes of stroke recurrence, major bleeding and intracranial bleeding were calculated based on the DerSimonian a …
Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis.
Huang B, et al. Arch Med Res 2012 - Review. PMID 22564422
BACKGROUND AND AIMS: Conclusions from clinical studies and previous meta-analyses were inconsistent regarding the cardiovascular effects of concomitant use of proton pump inhibitors (PPIs) and clopidogrel. As new studies are constantly emerging, we performed this meta-analysis to further assess the cardiovascular effects of concomitant use of PPIs and clopidogrel with a focus on individual PPIs. ...
BACKGROUND AND AIMS: Conclusions from clinical studies and previous meta-analyses were inconsistent regarding the cardiovascular effects
Ticlopidine.
[No authors listed] Lancet 1991. PMID 1671474
De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis
Angiolillo DJ, et al. J Thromb Thrombolysis 2019. PMID 31004312 Free PMC article.
De-escalation from ticagrelor to clopidogrel in acute coronary syndrome (ACS) may occur for a variety of reasons, including side effects (bleeding and non-bleeding) and costs. This study sought to assess the prevalence of de-escalation from ticagrelor to clopidogrel and the occurrence of adverse clinical outcomes following de-escalation. ...
De-escalation from ticagrelor to clopidogrel in acute coronary syndrome (ACS) may occur for a variety of reasons, including side effects
Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions
Klein MD, et al. Pharmacogenomics 2018 - Review. PMID 30028231
It is well established that the CYP2C19 nonfunctional *2 and *3 polymorphisms impair the bioactivation and antiplatelet effects of clopidogrel, and increase the risk of adverse cardiovascular events following percutaneous coronary intervention. ...
It is well established that the CYP2C19 nonfunctional *2 and *3 polymorphisms impair the bioactivation and antiplatelet effects of cl …
Adverse cutaneous reactions to ticlopidine in patients with coronary stents.
Yosipovitch G, et al. J Am Acad Dermatol 1999. PMID 10459126
A prospective study was carried out to assess the occurrence and character of adverse cutaneous reactions in patients receiving ticlopidine hydrochloride to prevent subacute thrombosis after having undergone placement of coronary stents. ...Only 3 patients had other adverse effects: neutropenia in 1 and abdominal pain and nausea in 2. The most common presentations were urticaria, pruritus, and maculopapular eruption. ...
A prospective study was carried out to assess the occurrence and character of adverse cutaneous reactions in patients receiving ti
2,713 results
Jump to page
Feedback